The short version of CJC-1295 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-23. Anything still debated is marked as such rather than presented as settled.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
A reading frame is defined by the initial triplet of nucleotides from which translation starts. It sets the frame for a run of successive, non-overlapping codons, which is known as an "open reading frame" (ORF). For example, the string 5'-AAATGAACG-3' (see figure), if read from the first position, contains the codons AAA, TGA, and ACG; if read from the second position, it contains the codons AAT and GAA; and if read from the third position, it contains the codons ATG and AAC. Every sequence can, thus, be read in its 5' → 3' direction in three reading frames, each producing a possibly distinct amino acid sequence: in the given example, Lys (K)-Trp (W)-Thr (T), Asn (N)-Glu (E), or Met (M)-Asn (N), respectively (when translating with the vertebrate mitochondrial code). When DNA is double-stranded, six possible reading frames are defined, three in the forward orientation on one strand and three reverse on the opposite strand. Protein-coding frames are defined by a start codon, usually the first AUG codon in the RNA, (ATG in DNA) sequence. In eukaryotes, open reading frames in exons are often interrupted by introns.
{\displaystyle {\underline {\underline {\boldsymbol {\varepsilon }}}}={\begin{bmatrix}\varepsilon _{xx}&\varepsilon _{xy}&\varepsilon _{xz}\\\varepsilon _{yx}&\varepsilon _{yy}&\varepsilon _{yz}\\\varepsilon _{zx}&\varepsilon _{zy}&\varepsilon _{zz}\\\end{bmatrix}}={\begin{bmatrix}\varepsilon _{xx}&{\tfrac {1}{2}}\gamma _{xy}&{\tfrac {1}{2}}\gamma _{xz}\\{\tfrac {1}{2}}\gamma _{yx}&\varepsilon _{yy}&{\tfrac {1}{2}}\gamma _{yz}\\{\tfrac {1}{2}}\gamma _{zx}&{\tfrac {1}{2}}\gamma _{zy}&\varepsilon _{zz}\\\end{bmatrix}}}
== Tritium breeding == Fusion reactions, such as those in the proposed ITER thermonuclear demonstrator reactor, are fueled by tritium and deuterium. Tritium resources are extremely limited in their availability, with total resources currently estimated at twenty kilograms. Lithium-containing ceramic pebbles can be used as solid breeder materials in a component known as a helium-cooled breeder blanket for the production of tritium. The breeding blanket constitutes a key component of the ITER reactor design. In such reactor designs tritium is produced by neutrons leaving the plasma and interacting with lithium in the blanket. Li2TiO3 along with Li4SiO4 are attractive as tritium breeding materials because they exhibit high tritium release, low activation, and chemical stability.
Nickel video from the Periodic Videos series (University of Nottingham) Nickel entry (last reviewed October 30, 2019) in the NIOSH Pocket Guide to Chemical Hazards published by the CDC's National Institute for Occupational Safety and Health Toxicological Profile for Nickel (draft for public comment) (PDF) (August 2023) – 422-page report from the United States Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry The metal that brought you cheap flights, BBC News (2015) usgs.gov: Nickel
== Early life and education == Meinrad Busslinger was born on 30 July 1952 in Gebenstorf, Switzerland. He grew up in the Swiss town of Zug, where he obtained his grammar school education. From 1972 to 1976, he studied natural sciences at the Swiss Federal Institute of Technology (ETH Zurich), where he majored in biochemistry. During his PhD studies (1976–1981), Busslinger discovered important regulatory elements involved in the transcriptional control of gene expression by investigating the regulation of sea urchin histone genes. He performed his PhD work under the supervision of Max L. Birnstiel at the University of Zurich, from where he received a PhD degree in molecular biology in 1981.
Sources: en.wikipedia.org
Xylazine is widely used in veterinary medicine as a sedative, muscle relaxant, and analgesic. It is frequently used in the treatment of tetanus. It is not used in human medical treatment. Xylazine is similar to drugs such as phenothiazines, tricyclic antidepressants, and clonidine. As an anesthetic, it is typically used in conjunction with ketamine. In animals, xylazine may be administered intramuscularly, intravenously, and intraosseously. Subcutaneous, oral transmusocal and intranasal have been investigated but are not standard routes for xylazine administration. As a veterinary anesthetic, xylazine is typically only administered once for the intended effect before or during surgical procedures. α2-Adrenergic receptor antagonists such as atipamezole and yohimbine may be used to reverse the effects of xylazine in animals. Xylazine is licensed for use in non-meat horses. Off-label use in cattle is common with recommended withholding periods of 1–5 days for dairy cattle and 4–10 days for meat cattle. Cattle are more sensitive to xylazine than horses with the sensitivity being greater in meat cattle breeds than dairy cattle breeds. Xylazine's use in cats and dogs is being replaced with the more selective alpha2 adrenergic receptor agonists medetomidine and dexmedetomidine and in some countries xylazine is rarely used with cats and dogs. High amounts of catecholamines in a patient will require higher doses of xylazine to be administered to provide sedation. The heightened levels required may not be practical or possible to administer and regular doses may cause excitement.
For services to People with Autism and their Families. Anoushé Husain. Ambassador, Ehlers Danlos Support UK, LimbPower and Disability Champion. For services to People with Disabilities. Neil Rankin Hutchison. Lately Engineer, Roche Diagnostics. For services to Laboratory Engineering. Dorothy Jeanne Hyett. Regional Access and Bridleway Officer for Wales, British Horse Society. For services to Horse Riders and Horse Welfare. Helen Louise Hyndman. Service Coordinator, Ask Eve, The Eve Appeal. For charitable services to Women with Gynaecological Cancers. Lydia Anna Obat Ina. Foster Carer and Founder, Gapolunya Foundation. For services to Vulnerable Children. Kenneth Ince. Scout Leader, 1st Golborne (St Thomas) Scout Group. For services to Young People in the Metropolitan Borough of Wigan. Sheila Ince. Cub Scout Leader, 1st Golborne (St Thomas) Scout Group. For services to Young People in the Metropolitan Borough of Wigan. Hazel Irvine. Sports Presenter, Honorary President, Enable Scotland. For services to Sport and to Charity. Leslie John Raymond Irvine. International Referee Assessor, Irish Football Association. For services to Association Football. Azara Issifu. Independent Family Group Conference Coordinator, London Borough of Camden. For services to Children and Families, and to the community in the London Borough of Camden. Douglas Michael Jackson. For services to the community in Sheffield, South Yorkshire. Christine May Jackson. Headteacher, Glasllwch County Primary School, Newport. For services to Education. Sabit Jakupović.
=== Protease Biology === Thanks to rapid advances in proteomics, genomics, and bioinformatics, protease research has been revolutionized. Degradomics emerged with the concept that proteolysis represents a specific mechanism for achieving cellular control over vital processes beyond control afforded by gene expression and translation and continues to produce the research necessary to understand the complex regulation of biology. Where it was thought extracellular proteases degraded extracellular matrix (ECM), these proteases are now known to target and process a vast array of substrates with diverse roles, redefining protease functions and leading to a shift in interest towards new roles previously unknown to biology. Degradomic studies of human tissue have also contributed to the Human Proteome Project (HPP) of the Human Proteome Organization (HUPO).
differs when considering the effects of vaccinations and when the real-time dependence of fatality and recovery rates diverge. These differences have been highlighted for stationary ratios and gradually decreasing fatality rates. The case of stationary ratios allows one to construct a diagnostics method to extract analytically all SIRVD model parameters from measured COVID-19 data of a completed pandemic wave.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.